Cited 21 times in
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이현웅 | - |
dc.date.accessioned | 2022-11-24T00:51:41Z | - |
dc.date.available | 2022-11-24T00:51:41Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191047 | - |
dc.description.abstract | Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular carcinoma (HCC) patients after the phase III RESORCE trial. This study analyzed real-world data to assess the clinical effectiveness and safety of regorafenib compared to the RESORCE trial. Methods This multicenter cohort study included HCC patients treated with regorafenib after sorafenib (n = 133). We evaluated the time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety in patients receiving regorafenib along with the predictors of prognosis. Results The median age was 60 years and 81.2% patients were men. Hepatitis B virus infection (68.4%) was the commonest etiology. Most patients were classified as Child-Pugh A (98.5%) and had extrahepatic metastasis (84%) and vascular invasion (45.1%). This study demonstrated similar characteristics apart from more frequent hepatitis B etiology and more vascular or extrahepatic involvement compared with the RESORCE trial. An objective response rate of 12.5% was obtained for response assessment (n = 112); the disease control rate was 34.8%. Thirty-eight patients died during follow-up. With regorafenib, the median OS, PFS, and TTP were 10.0, 2.7, and 2.6 months, respectively. In the exploratory analysis after sorafenib administration, the median OS was 25.8 months. The rate of response and survival were comparable to those in the RESORCE trial. Child-Pugh score > 5, alpha-fetoprotein > 400 ng/ml, and TTP for sorafenib ≥ median were independently associated with OS. Conclusions This real-word regorafenib study showed comparable effectiveness and safety to the RESORCE trial. Regorafenib improves the prognosis of patients with prolonged TTP during previous sorafenib therapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | INVESTIGATIONAL NEW DRUGS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Age Factors | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents / administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents / adverse effects | - |
dc.subject.MESH | Antineoplastic Agents / therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Carcinoma, Hepatocellular / drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular / mortality | - |
dc.subject.MESH | Carcinoma, Hepatocellular / pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Liver Neoplasms / drug therapy* | - |
dc.subject.MESH | Liver Neoplasms / mortality | - |
dc.subject.MESH | Liver Neoplasms / pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Patient Acuity | - |
dc.subject.MESH | Phenylurea Compounds / administration & dosage | - |
dc.subject.MESH | Phenylurea Compounds / adverse effects | - |
dc.subject.MESH | Phenylurea Compounds / therapeutic use* | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Pyridines / administration & dosage | - |
dc.subject.MESH | Pyridines / adverse effects | - |
dc.subject.MESH | Pyridines / therapeutic use* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Sex Factors | - |
dc.subject.MESH | Sorafenib / administration & dosage | - |
dc.subject.MESH | Sorafenib / adverse effects | - |
dc.subject.MESH | Sorafenib / therapeutic use* | - |
dc.title | Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Min Jin Lee | - |
dc.contributor.googleauthor | Sung Won Chang | - |
dc.contributor.googleauthor | Ji Hoon Kim | - |
dc.contributor.googleauthor | Young-Sun Lee | - |
dc.contributor.googleauthor | Sung Bum Cho | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Hyung Joon Yim | - |
dc.contributor.googleauthor | Sang Youn Hwang | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.contributor.googleauthor | Young Chang | - |
dc.contributor.googleauthor | Jae Young Jang | - |
dc.identifier.doi | 10.1007/s10637-020-00977-4 | - |
dc.contributor.localId | A03292 | - |
dc.relation.journalcode | J01184 | - |
dc.identifier.eissn | 1573-0646 | - |
dc.identifier.pmid | 32749658 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s10637-020-00977-4 | - |
dc.subject.keyword | Effectiveness | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Real-world study | - |
dc.subject.keyword | Safety | - |
dc.contributor.alternativeName | Lee, Hyun Woong | - |
dc.contributor.affiliatedAuthor | 이현웅 | - |
dc.citation.volume | 39 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 260 | - |
dc.citation.endPage | 268 | - |
dc.identifier.bibliographicCitation | INVESTIGATIONAL NEW DRUGS, Vol.39(1) : 260-268, 2021-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.